140 related articles for article (PubMed ID: 38387093)
21. Langerhans cell histiocytosis: A neoplastic disorder driven by Ras-ERK pathway mutations.
Tran G; Huynh TN; Paller AS
J Am Acad Dermatol; 2018 Mar; 78(3):579-590.e4. PubMed ID: 29107340
[TBL] [Abstract][Full Text] [Related]
22. Mutant BRAF Upregulates MCL-1 to Confer Apoptosis Resistance that Is Reversed by MCL-1 Antagonism and Cobimetinib in Colorectal Cancer.
Kawakami H; Huang S; Pal K; Dutta SK; Mukhopadhyay D; Sinicrope FA
Mol Cancer Ther; 2016 Dec; 15(12):3015-3027. PubMed ID: 27765849
[TBL] [Abstract][Full Text] [Related]
23. Remission of Congenital Multi-system Type Langerhans Cell Histiocytosis with Chemotherapy.
Tamefusa K; Ishida H; Washio K; Ishida T; Morita H; Shimada A
Acta Med Okayama; 2019 Feb; 73(1):61-65. PubMed ID: 30820055
[TBL] [Abstract][Full Text] [Related]
24. [Elucidated pathogenesis and therapeutic prospects in Langerhans cell histiocytosis].
Morimoto A; Shioda Y; Sakamoto K; Kudo K; Imamura T; Kudo K
Rinsho Ketsueki; 2022; 63(5):373-382. PubMed ID: 35662160
[TBL] [Abstract][Full Text] [Related]
25. Clinical features and treatment outcomes of pediatric Langerhans cell histiocytosis with macrophage activation syndrome-hemophagocytic lymphohistiocytosis.
Wang D; Chen XH; Wei A; Zhou CJ; Zhang X; Ma HH; Lian HY; Zhang L; Zhang Q; Huang XT; Wang CJ; Yang Y; Liu W; Wang TY; Li ZG; Cui L; Zhang R
Orphanet J Rare Dis; 2022 Apr; 17(1):151. PubMed ID: 35379272
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of the MEK inhibitor cobimetinib for wild-type BRAF Erdheim-Chester disease.
Cohen Aubart F; Emile JF; Maksud P; Galanaud D; Cluzel P; Benameur N; Aumaitre O; Amoura Z; Haroche J
Br J Haematol; 2018 Jan; 180(1):150-153. PubMed ID: 27711968
[No Abstract] [Full Text] [Related]
27. A first-in-human phase I study to evaluate the MEK1/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumors.
Rosen LS; LoRusso P; Ma WW; Goldman JW; Weise A; Colevas AD; Adjei A; Yazji S; Shen A; Johnston S; Hsieh HJ; Chan IT; Sikic BI
Invest New Drugs; 2016 Oct; 34(5):604-13. PubMed ID: 27424159
[TBL] [Abstract][Full Text] [Related]
28. Cobimetinib and trametinib inhibit platelet MEK but do not cause platelet dysfunction.
Unsworth AJ; Bye AP; Kriek N; Sage T; Osborne AA; Donaghy D; Gibbins JM
Platelets; 2019; 30(6):762-772. PubMed ID: 30252580
[TBL] [Abstract][Full Text] [Related]
29. A fatal case of congenital disseminated Langerhans cell histiocytosis.
Goñi-Orayen C; Ruiz-Cano R; Pérez-Martínez A; Escario-Travesedo E; Atienzar-Tobarra M; Martínez-Gutiérrez A
J Perinat Med; 1999; 27(3):228-30. PubMed ID: 10503186
[TBL] [Abstract][Full Text] [Related]
30. Long-term complete response after treatment with cytarabine, vincristine, and prednisone in an infant with refractory multisystem Langerhans cell histiocytosis.
Cook R; Berkow RL; Kelly DR; Friedman GK
Pediatr Blood Cancer; 2011 Jul; 57(1):180-1. PubMed ID: 21412968
[No Abstract] [Full Text] [Related]
31. Inflammatory serum cytokines and chemokines increase associated with the disease extent in pediatric Langerhans cell histiocytosis.
Morimoto A; Oh Y; Nakamura S; Shioda Y; Hayase T; Imamura T; Kudo K; Imashuku S;
Cytokine; 2017 Sep; 97():73-79. PubMed ID: 28582647
[TBL] [Abstract][Full Text] [Related]
32. Analysis of the BRAF and MAP2K1 mutations in patients with Langerhans cell histiocytosis in Japan.
Hayase T; Saito S; Shioda Y; Imamura T; Watanabe K; Ohki K; Yoshioka T; Oh Y; Kawahara Y; Niijima H; Imashuku S; Morimoto A
Int J Hematol; 2020 Oct; 112(4):560-567. PubMed ID: 32654047
[TBL] [Abstract][Full Text] [Related]
33. Differentiating skin-limited and multisystem Langerhans cell histiocytosis.
Simko SJ; Garmezy B; Abhyankar H; Lupo PJ; Chakraborty R; Lim KP; Shih A; Hicks MJ; Wright TS; Levy ML; McClain KL; Allen CE
J Pediatr; 2014 Nov; 165(5):990-6. PubMed ID: 25441388
[TBL] [Abstract][Full Text] [Related]
34. Multisystem Langerhans cell histiocytosis in children: current treatment and future directions.
Minkov M
Paediatr Drugs; 2011 Apr; 13(2):75-86. PubMed ID: 21351807
[TBL] [Abstract][Full Text] [Related]
35. Langerhans cell histiocytosis: promises and caveats of targeted therapies in high-risk and CNS disease.
Abla O
Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):386-395. PubMed ID: 38066856
[TBL] [Abstract][Full Text] [Related]
36. High Prevalence of
Liu X; Zhang Y; Zhou CX
Int J Surg Pathol; 2019 Dec; 27(8):836-843. PubMed ID: 31203679
[TBL] [Abstract][Full Text] [Related]
37. Treatment of Langerhans cell histiocytosis: role of BRAF/MAPK inhibition.
Abla O; Weitzman S
Hematology Am Soc Hematol Educ Program; 2015; 2015():565-70. PubMed ID: 26637773
[TBL] [Abstract][Full Text] [Related]
38. BRAF V600E mutation in childhood Langerhans cell histiocytosis correlates with multisystem disease and poor survival.
Bhatia P; Singh M; Sharma M; Sharma A; Kakkar N; Radhika S; Trehan A; Bansal D
Blood Cells Mol Dis; 2020 May; 82():102356. PubMed ID: 32171112
[TBL] [Abstract][Full Text] [Related]
39. Lung Involvement in Destombes-Rosai-Dorfman Disease: Clinical and Radiological Features and Response to the MEK Inhibitor Cobimetinib.
Moyon Q; Boussouar S; Maksud P; Emile JF; Charlotte F; Aladjidi N; Prévot G; Donadieu J; Amoura Z; Grenier P; Haroche J; Cohen Aubart F
Chest; 2020 Feb; 157(2):323-333. PubMed ID: 31669429
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of BRAF-Inhibitor Therapy in BRAF
Hazim AZ; Ruan GJ; Ravindran A; Abeykoon JP; Scheckel C; Vassallo R; Ryu JH; Tobin WO; Koster MJ; Bennani NN; Rech KL; Young JR; Shah MV; Goyal G; Go RS
Oncologist; 2020 Dec; 25(12):1001-1004. PubMed ID: 32985015
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]